Design, Synthesis And Biological Evaluation Of Novel Lead Compounds For Treatment Of Fibrodysplasia
33/10/2019-TF/Rare/BMS
ICMR
Dec. 21, 2020
Dec. 20, 2023
Three Year
Fibrodysplasia Ossificans Progressiva
None
None
To design a structure-based pharmacophore for target ACVR1, followed by virtually screening of databases in order to identify small molecule inhibitors of ACVR1 and their biological evaluation in tran
Fibrodysplasia Ossificans progressiva, ACVR1, ALK2, Pharmacophore, Zebrafish, bone morphogenetic pro
None
40,84,855/-
Dr. Indrakant K. Singh/None/Deshbandhu college